Spots Global Cancer Trial Database for A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Official Title: A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors
Study ID: NCT05954312
Conditions
Interventions
Study Description
Brief Summary: A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Cancer Specialists, Sarasota, Florida, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
MDACC, Houston, Texas, United States
NEXT Dallas, Irving, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
START Barcelona Hospital HM Nou Delfos, Barcelona, , Spain
NEXT Madrid, Madrid, , Spain
START Madrid CIOCC, Madrid, , Spain
Start Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
